Steffen Pabel

Steffen Pabel

Auto-generated profile, based on publicly available information

Steffen Pabel

Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2026 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
NMNoor Momin
Noor Momin
SPSteffen Pabel
Steffen Pabel
Arnab RudraArnab Rudra
Arnab Rudra
NKNina Kumowski
Nina Kumowski
ILI-Hsiu Lee
I-Hsiu Lee
MHMaarten Hulsmans
Maarten Hulsmans

1 November 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
MKMaria Knierim
Maria Knierim
TBThea Bommer
Thea Bommer
MPMichael Paulus
Michael Paulus
DRDominic Riedl
Dominic Riedl
SFSarah Fink
Sarah Fink
SPSteffen Pabel
Steffen Pabel
Electric pacing is increasingly used in research with human induced pluripotent stem cell cardiomyocytes (hiPSC-CM), for example to simulate arrhythmias but also to enhance maturity. Therefore, it is mandatory to understand the effects of pacing itself on cellular electrophysiology in late-stage, matured hiPSC-CM. This study provides an electrophysiological characterization of the effects of chronic electric pacing at a physiological rate on differentiated hiPSC-CM.

8 October 2025 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MYMasahiro Yamazoe
Masahiro Yamazoe
KTKenneth K. Y. Ting
Kenneth K. Y. Ting
ILI-Hsiu Lee
I-Hsiu Lee
ABAneesh Bapat
Aneesh Bapat
ALAndrew Lewis
Andrew Lewis
MNMatthias Nahrendorf
Matthias Nahrendorf
Atrial fibrillation, the most frequent cardiac arrhythmia, causes heart failure and stroke. Here we describe that combining the typical risk factors of atrial fibrillation (hypertension, obesity and mitral valve regurgitation (HOMER)) activates adaptive immunity in wild-type mice, ultimately causing electrical remodeling of cardiomyocytes. In HOMER mice, dendritic cells expanded in the left atria and heart-draining lymph nodes, where we detected cardiomyocyte-derived proteins. Systemically expanding B cells, while exposed to interferon-α, produced autoantibodies that disrupted calcium handling in cardiomyocytes. Depleting B cells by using μMT HOMER mice or plasma cells by using Mb1cre/+ Prdm1fl/fl HOMER mice reduced atrial fibrillation while mitigating the prolonged action potential duration we observed in the left atria of HOMER mice. CD20 antibody B cell depletion, a clinical tool in treating lymphoma and autoimmune disease, reduced atrial fibrillation fivefold in HOMER mice. Targeting humoral immunity may provide therapeutic avenues for patients with autoantibody-induced atrial fibrillation.

24 September 2025 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
SKSumeet A. Khetarpal
Sumeet A. Khetarpal
HLHaobo Li
Haobo Li
TVTevis Vitale
Tevis Vitale
JRJames Rhee
James Rhee
SCSaketh Challa
Saketh Challa
ARAnthony Rosenzweig
Anthony Rosenzweig

27 September 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TBThea Bommer
Thea Bommer
MKMaria Knierim
Maria Knierim
JUJulia Unsöld
Julia Unsöld
DRDominic Riedl
Dominic Riedl
LSLaura Stengel
Laura Stengel
SPSteffen Pabel
Steffen Pabel
The effects and mechanisms of cardiac arrhythmias are still incompletely understood and an important subject of cardiovascular research. A major difficulty for investigating arrhythmias is the lack of appropriate human models. Here, we present a protocol for a translational simulation of different types of arrhythmias using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and electric cell culture pacing. The protocol comprises the handling of ventricular and atrial hiPSC-CM before and during in vitro arrhythmia simulation and possible arrhythmia simulation protocols mimicking clinical arrhythmias like atrial fibrillation. Isolated or confluent hiPSC-CM can be used for the simulation. In vitro arrhythmia simulation did not impair cell viability of hiPSC-CM and could reproduce arrhythmia associated phenotypes of patients. The use of hiPSC-CM enables patient-specific studies of arrhythmias, genetic interventions, or drug-screening. Thus, the in vitro arrhythmia simulation protocol may offer a versatile tool for translational studies on the mechanisms and treatment options of cardiac arrhythmias.

1 March 2026 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
JRJudith Rees
Judith Rees
AWAnnika Winkler
Annika Winkler
JHJudith Huettemeister
Judith Huettemeister
LSLaura Stengel
Laura Stengel
PSPaul Spangler
Paul Spangler
NHNiklas Hegemann
Niklas Hegemann
This study evaluates rostafuroxin, a selective ouabain inhibitor, for its potential to antagonize electrophysiological derangements in ouabain overdosing. Methodologically, the study uses the iCE model, previously introduced as a suitable 3 R-compliant cardiovascular research platform. We developed and validated a comprehensive electrophysiological workflow in iCEs to perform our investigations. Ouabain increased heart rate variability, induced arrhythmia and electrolyte imbalances in iCEs, whereas rostafuroxin largely protected them from these effects.